Metabolic stress in insulin's target cells leads to ROS accumulation - A hypothetical common pathway causing insulin resistance

FEBS Letters

Volumn 581, Issue 19, 2007, Pages 3734-3742

  Eriksson, Jan W ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adipocyte; Glucotoxicity; Insulin resistance; Lipotoxicity; Metabolic syndrome; Oxidative stress; Reactive oxygen species; Stress; Type 2 diabetes

Indexed keywords

CYTOKINE; FATTY ACID; GLUCOSE; HORMONE; REACTIVE OXYGEN METABOLITE;

ADIPOCYTE; ADIPOSE TISSUE; CARDIOVASCULAR RISK; DISEASE COURSE; HORMONAL REGULATION; HUMAN; HYPOTHESIS; INSULIN RESISTANCE; METABOLIC DISORDER; METABOLIC STRESS; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; SIGNAL TRANSDUCTION;

ADIPOSE TISSUE; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; INSULIN RESISTANCE; METABOLIC SYNDROME X; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 34447625413     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2007.06.044     Document Type: Short Survey

References (63)

1. Kyrou I., Chrousos G.P., and Tsigos C. Stress, visceral obesity, and metabolic complications. Ann. NY Acad. Sci. 1083 (2006) 77-110
2. Robertson R.P. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J. Biol. Chem. 279 (2004) 42351-42354
3. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 (2005) 1615-1625
4. Evans J.L., Goldfine I.D., Maddux B.A., and Grodsky G.M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev. 23 (2002) 599-622
5. Evans J.L., Maddux B.A., and Goldfine I.D. The molecular basis for oxidative stress-induced insulin resistance. Antioxid. Redox Signal. 7 (2005) 1040-1052
6. Ritchie S.A., and Connell J.M. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr. Metab. Cardiovasc. Dis. 17 (2007) 319-326
7. Kahn B.B., and Flier J.S. Obesity and insulin resistance. J. Clin. Invest. 106 (2000) 473-481
8. Sladek R., Rocheleau G., Rung J., Dina C., Shen L., Serre D., Boutin P., Vincent D., Belisle A., Hadjadj S., Balkau B., Heude B., Charpentier G., Hudson T.J., Montpetit A., Pshezhetsky A.V., Prentki M., Posner B.I., Balding D.J., Meyre D., Polychronakos C., and Froguel P. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445 (2007) 881-885
9. Watson R.T., Shigematsu S., Chiang S.H., Mora S., Kanzaki M., Macara I.G., Saltiel A.R., and Pessin J.E. Lipid raft microdomain compartmentalization of tc10 is required for insulin signaling and glut4 translocation. J. Cell Biol. 154 (2001) 829-840
10. Zierath J.R., Galuska D., Nolte L.A., Thorne A., Kristensen J.S., and Wallberg-Henriksson H. Effects of glycaemia on glucose transport in isolated skeletal muscle from patients with niddm: in vitro reversal of muscular insulin resistance. Diabetologia 37 (1994) 270-277
11. Buren J., Lindmark S., Renstrom F., and Eriksson J.W. In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: Is cellular insulin resistance caused by glucotoxicity in vivo?. Metabolism 52 (2003) 239-245
12. Buren J., and Eriksson J.W. Is insulin resistance caused by defects in insulin's target cells or by a stressed mind?. Diabetes Metab. Res. Rev. 21 (2005) 487-494
13. Phillips D.I. Programming of the stress response: a fundamental mechanism underlying the long-term effects of the fetal environment?. J. Intern. Med. 261 (2007) 453-460
14. Yudkin J.S., Juhan-Vague I., Hawe E., Humphries S.E., di Minno G., Margaglione M., Tremoli E., Kooistra T., Morange P.E., Lundman P., Mohamed-Ali V., and Hamsten A. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the hifmech study. Metabolism 53 (2004) 852-857
15. Garvey W.T., Olefsky J.M., and Marshall S. Insulin induces progressive insulin resistance in cultured rat adipocytes. Sequential effects at receptor and multiple postreceptor sites. Diabetes 35 (1986) 258-267
16. Yki-Jarvinen H. Toxicity of hyperglycaemia in type 2 diabetes. Diabetes Metab. Rev. 14 Suppl. 1 (1998) S45-S50
17. Renstrom F., Buren J., and Eriksson J.W. Insulin receptor substrates-1 and -2 are both depleted but via different mechanisms after down-regulation of glucose transport in rat adipocytes. Endocrinology 146 (2005) 3044-3051
18. Renstrom F., Buren J., Svensson M., and Eriksson J.W. Insulin resistance induced by high glucose and high insulin precedes insulin receptor substrate 1 protein depletion in human adipocytes. Metabolism 56 (2007) 190-198
19. Carvalho E., Jansson P.A., Axelsen M., Eriksson J.W., Huang X., Groop L., Rondinone C., Sjostrom L., and Smith U. Low cellular irs 1 gene and protein expression predict insulin resistance and niddm. Faseb J. 13 (1999) 2173-2178
20. Rondinone C.M., Wang L.M., Lonnroth P., Wesslau C., Pierce J.H., and Smith U. Insulin receptor substrate (irs) 1 is reduced and irs-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc. Natl. Acad. Sci. USA 94 (1997) 4171-4175
21. Roden M., Price T.B., Perseghin G., Petersen K.F., Rothman D.L., Cline G.W., and Shulman G.I. Mechanism of free fatty acid-induced insulin resistance in humans. J. Clin. Invest. 97 (1996) 2859-2865
22. Lundgren M., and Eriksson J.W. No in vitro effects of fatty acids on glucose uptake, lipolysis or insulin signaling in rat adipocytes. Horm. Metab. Res. 36 (2004) 203-209
23. Zhou Y.P., and Grill V.E. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J. Clin. Invest. 93 (1994) 870-876
24. Schmitz-Peiffer C., and Whitehead J.P. Irs-1 regulation in health and disease. IUBMB Life 55 (2003) 367-374
25. Yu C., Chen Y., Cline G.W., Zhang D., Zong H., Wang Y., Bergeron R., Kim J.K., Cushman S.W., Cooney G.J., Atcheson B., White M.F., Kraegen E.W., and Shulman G.I. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (irs-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277 (2002) 50230-50236
26. Lin Y., Berg A.H., Iyengar P., Lam T.K., Giacca A., Combs T.P., Rajala M.W., Du X., Rollman B., Li W., Hawkins M., Barzilai N., Rhodes C.J., Fantus I.G., Brownlee M., and Scherer P.E. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J. Biol. Chem. 280 (2005) 4617-4626
27. Benthem L., Keizer K., Wiegman C.H., de Boer S.F., Strubbe J.H., Steffens A.B., Kuipers F., and Scheurink A.J. Excess portal venous long-chain fatty acids induce syndrome x via hpa axis and sympathetic activation. Am. J. Physiol. Endocrinol. Metab. 279 (2000) E1286-E1293
28. Lindmark S., Buren J., and Eriksson J.W. Insulin resistance, endocrine function and adipokines in type 2 diabetes patients at different glycaemic levels: Potential impact for glucotoxicity in vivo. Clin. Endocrinol. (Oxford) 65 (2006) 301-309
29. Brunner E.J., Hemingway H., Walker B.R., Page M., Clarke P., Juneja M., Shipley M.J., Kumari M., Andrew R., Seckl J.R., Papadopoulos A., Checkley S., Rumley A., Lowe G.D., Stansfeld S.A., and Marmot M.G. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: Nested case-control study. Circulation 106 (2002) 2659-2665
30. Rask E., Olsson T., Soderberg S., Andrew R., Livingstone D.E., Johnson O., and Walker B.R. Tissue-specific dysregulation of cortisol metabolism in human obesity. J. Clin. Endocrinol. Metab. 86 (2001) 1418-1421
31. Lundgren M., Buren J., Ruge T., Myrnas T., and Eriksson J.W. Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes. J. Clin. Endocrinol. Metab. 89 (2004) 2989-2997
32. Delaunay F., Khan A., Cintra A., Davani B., Ling Z.C., Andersson A., Ostenson C.G., Gustafsson J., Efendic S., and Okret S. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J. Clin. Invest. 100 (1997) 2094-2098
33. Lindmark S., Wiklund U., Bjerle P., and Eriksson J.W. Does the autonomic nervous system play a role in the development of insulin resistance? A study on heart rate variability in first-degree relatives of type 2 diabetes patients and control subjects. Diabet. Med. 20 (2003) 399-405
34. Laitinen T., Vauhkonen I.K., Niskanen L.K., Hartikainen J.E., Lansimies E.A., Uusitupa M.I., and Laakso M. Power spectral analysis of heart rate variability during hyperinsulinemia in nondiabetic offspring of type 2 diabetic patients: evidence for possible early autonomic dysfunction in insulin-resistant subjects. Diabetes 48 (1999) 1295-1299
35. Lind L., Pollare T., Berne C., and Lithell H. Long-term metabolic effects of antihypertensive drugs. Am. Heart J. 128 (1994) 1177-1183
36. Sharma A.M., Janke J., Gorzelniak K., Engeli S., and Luft F.C. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 40 (2002) 609-611
37. Rotter V., Nagaev I., and Smith U. Interleukin-6 (il-6) induces insulin resistance in 3t3-l1 adipocytes and is, like il-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J. Biol. Chem. 278 (2003) 45777-45784
38. Tomlinson J.W., Moore J., Cooper M.S., Bujalska I., Shahmanesh M., Burt C., Strain A., Hewison M., and Stewart P.M. Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: Tissue-specific induction by cytokines. Endocrinology 142 (2001) 1982-1989
39. Eller N.H., Netterstrom B., and Hansen A.M. Psychosocial factors at home and at work and levels of salivary cortisol. Biol. Psychol. 73 (2006) 280-287
40. Bjorntorp P., and Rosmond R. Neuroendocrine abnormalities in visceral obesity. Int. J. Obes. Relat. Metab. Disord. 24 Suppl. 2 (2000) S80-S85
41. Lindmark S., Lonn L., Wiklund U., Tufvesson M., Olsson T., and Eriksson J.W. Dysregulation of the autonomic nervous system can be a link between visceral adiposity and insulin resistance. Obes. Res. 13 (2005) 717-728
42. Bjorntorp P., Holm G., and Rosmond R. Hypothalamic arousal, insulin resistance and type 2 diabetes mellitus. Diabet. Med. 16 (1999) 373-383
43. Harman-Boehm I., Bluher M., Redel H., Sion-Vardy N., Ovadia S., Avinoach E., Shai I., Kloting N., Stumvoll M., Bashan N., and Rudich A. Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the co-morbidities of obesity. J. Clin. Endocrinol. Metab. 92 (2007) 2240-2247
44. Arner P. Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract. Res. Clin. Endocrinol. Metab. 19 (2005) 471-482
45. Rasouli N., Molavi B., Elbein S.C., and Kern P.A. Ectopic fat accumulation and metabolic syndrome. Diabetes Obes. Metab. 9 (2007) 1-10
46. Hammarstedt A., Isakson P., Gustafson B., and Smith U. Wnt-signaling is maintained and adipogenesis inhibited by TNFα but not MCP-1 and resistin. Biochem. Biophys. Res. Commun. 357 (2007) 700-706
47. Lundgren M., Svensson M., Lindmark S., Renstrom F., Ruge T., and Eriksson J.W. Fat cell enlargement is an independent marker of insulin resistance and 'hyperleptinaemia'. Diabetologia 50 (2007) 625-633
48. Weyer C., Foley J.E., Bogardus C., Tataranni P.A., and Pratley R.E. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia 43 (2000) 1498-1506
49. Baile C.A., Della-Fera M.A., and Martin R.J. Regulation of metabolism and body fat mass by leptin. Annu. Rev. Nutr. 20 (2000) 105-127
50. Hennige A.M., Stefan N., Kapp K., Lehmann R., Weigert C., Beck A., Moeschel K., Mushack J., Schleicher E., and Haring H.U. Leptin down-regulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1. Faseb J. 20 (2006) 1206-1208
51. Pellme F., Smith U., Funahashi T., Matsuzawa Y., Brekke H., Wiklund O., Taskinen M.R., and Jansson P.A. Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 52 (2003) 1182-1186
52. Yamauchi T., Nio Y., Maki T., Kobayashi M., Takazawa T., Iwabu M., Okada-Iwabu M., Kawamoto S., Kubota N., Kubota T., Ito Y., Kamon J., Tsuchida A., Kumagai K., Kozono H., Hada Y., Ogata H., Tokuyama K., Tsunoda M., Ide T., Murakami K., Awazawa M., Takamoto I., Froguel P., Hara K., Tobe K., Nagai R., Ueki K., and Kadowaki T. Targeted disruption of adipor1 and adipor2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med. 13 (2007) 332-339
53. Fain J.N., Madan A.K., Hiler M.L., Cheema P., and Bahouth S.W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145 (2004) 2273-2282
54. Houstis N., Rosen E.D., and Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440 (2006) 944-948
55. Perreault M., and Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat. Med. 7 (2001) 1138-1143
56. Aronis A., Madar Z., and Tirosh O. Mechanism underlying oxidative stress-mediated lipotoxicity: Exposure of j774.2 macrophages to triacylglycerols facilitates mitochondrial reactive oxygen species production and cellular necrosis. Free Radic. Biol. Med. 38 (2005) 1221-1230
57. Fujita K., Nishizawa H., Funahashi T., Shimomura I., and Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ. J. 70 (2006) 1437-1442
58. Haber C.A., Lam T.K., Yu Z., Gupta N., Goh T., Bogdanovic E., Giacca A., and Fantus I.G. N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: possible role of oxidative stress. Am. J. Physiol. Endocrinol. Metab. 285 (2003) E744-E753
59. Wright Jr. E., Scism-Bacon J.L., and Glass L.C. Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int. J. Clin. Pract. 60 (2006) 308-314
60. Mogensen M., Sahlin K., Fernstrom M., Glintborg D., Vind B.F., Beck-Nielsen H., and Hojlund K. Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes 56 (2007) 1592-1599
61. White M., Lepage S., Lavoie J., De Denus S., Leblanc M.H., Gossard D., Whittom L., Racine N., Ducharme A., Dabouz F., Rouleau J.L., and Touyz R. Effects of combined candesartan and ace inhibitors on bnp, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure. J. Card. Fail. 13 (2007) 86-94
62. Ferder L., Inserra F., and Martinez-Maldonado M. Inflammation and the metabolic syndrome: Role of angiotensin ii and oxidative stress. Curr. Hypertens. Rep. 8 (2006) 191-198
63. Van Gaal L.F., Mertens I.L., and De Block C.E. Mechanisms linking obesity with cardiovascular disease. Nature 444 (2006) 875-880